drugset / Trial / NCT04094896
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
Timeline
- Start
- 2019-09-17
- Primary completion
- 2022-09-17
- Completion
- 2022-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Epirubicin | Small molecule | — | — |
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |